Intravenous (IV) Equipment Market Size and Share
Intravenous (IV) Equipment Market Analysis by Mordor Intelligence
The IV therapy devices market size stands at USD 16.34 billion in 2025 and is projected to reach USD 22.07 billion by 2030, registering a 6.20% CAGR over the forecast period. Supply-chain fragility became clear when Hurricane Helene forced Baxter to shut its North Carolina plant, eliminating 60% of US IV fluid capacity and prompting hospitals to cut usage by up to 55%[1]Source: NPR Staff, “Hurricane Helene Shuts Baxter Plant And Triggers IV Fluid Shortage,” npr.org . The disruption accelerated point-of-care fluid production pilots and broadened calls for diversified sourcing. Regulatory pressure after multiple Class I recalls has pushed manufacturers toward AI-enabled safety features, driving rapid uptake of smart infusion systems. Asia-Pacific’s healthcare build-out and chronic-disease burden underpin the fastest regional expansion even as North America remains the revenue anchor. Intensifying M&A, illustrated by Stryker’s USD 4.9 billion acquisition of Inari Medical, signals a shift toward portfolio convergence that bundles pumps, catheters, and monitoring into integrated platforms.
Key Report Takeaways
- By product type, IV catheters led with 38.34% of the IV therapy devices market share in 2024, whereas smart infusion pumps are forecast to deliver a 6.78% CAGR to 2030.
- By end user, hospitals held 49.23% revenue share in 2024; home-care settings are expected to expand at a 7.12% CAGR through 2030.
- By application, chemotherapy and oncology accounted for 7.89% CAGR growth, outpacing medication administration’s 44.45% revenue share baseline in 2024.
- By geography, North America captured 42.23% of total revenue in 2024, while Asia-Pacific is projected to rise at an 8.12% CAGR between 2025 and 2030.
Global Intravenous (IV) Equipment Market Trends and Insights
Driver Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rising prevalence of chronic diseases requiring long-term IV therapy | +1.8% | Global, with concentration in aging populations of North America, Europe, and Japan | Long term (≥ 4 years) |
Growth in home- and ambulatory-based infusion therapy | +1.2% | North America & EU leading, APAC emerging markets following | Medium term (2-4 years) |
Increasing surgical procedures & hospitalization rates | +0.9% | APAC core markets, spill-over to MEA and Latin America | Medium term (2-4 years) |
Technological advancements in smart infusion & needle-free systems | +0.8% | Global, with early adoption in developed markets | Short term (≤ 2 years) |
Emergence of closed-loop AI drug-delivery algorithms | +0.5% | North America & EU, limited APAC penetration | Long term (≥ 4 years) |
Decentralized clinical trials driving portable IV devices | +0.3% | Global, concentrated in major pharmaceutical hubs | Medium term (2-4 years) |
Source: Mordor Intelligence
Rising Prevalence of Chronic Diseases Requiring Long-Term IV Therapy
Diabetes affects 537 million adults and often necessitates intravenous intervention for complications, underpinning predictable demand across the IV therapy devices market[2]Source: MIT News, “Closed-Loop Drug-Delivery System Could Improve Chemotherapy,” news.mit.edu . Aging populations in North America, Europe, and Japan further widen the chronic-care pool that relies on multi-drug regimens unsuitable for oral delivery. MIT’s CLAUDIA system exemplifies the push toward closed-loop chemotherapy that automatically adjusts dosing every five minutes, illustrating how disease complexity spurs advanced infusion adoption. Payers support home-based IV services to curb readmissions, reinforcing a durable revenue stream for manufacturers that supply patient-centric delivery platforms. Together, these forces propel sustained growth momentum within the IV therapy devices market.
Growth in Home- and Ambulatory-Based Infusion Therapy
Veterans Affairs saved USD 10.2 million by substituting inpatient care with home infusion, validating an economic case that pressures providers to shift toward ambulatory models academic.oup.com. Portable pumps such as the Infonde unit record 95% patient-satisfaction rates, underscoring how mobility-friendly technology supports quality-of-life goals. Pending US legislation proposes stronger Medicare reimbursement, likely boosting patient volumes. During the COVID-19 pandemic, nurses operated pumps outside ICU rooms to reduce exposure risks, accelerating digital-monitoring upgrades. Oncology remains the prime home-care growth engine as patients favor familiar settings for lengthy chemotherapies, reinforcing upward momentum in the IV therapy devices market.
Increasing Surgical Procedures & Hospitalization Rates
Rising surgical volumes across Asia-Pacific require precise perioperative fluid management that smart pumps provide. BD’s HemoSphere Alta platform integrates Hypotension Prediction Index analytics, illustrating how AI-based decision support elevates pump utility during complex procedures. ERAS protocols demonstrated 50% fluid-use reductions without compromising outcomes, driving hospitals to adopt pumps capable of more granular delivery. Minimally invasive techniques and an aging population spur ongoing operating-room demand, sustaining the IV therapy devices market trajectory.
Technological Advancements in Smart Infusion & Needle-Free Systems
FDA guidance now permits software updates under predetermined change-control plans, accelerating AI innovation cycles in infusion devices. Needle-free connectors like Delta P.Valve achieve neonatal-safe flow rates while offering clear visualization to avert infection deltamed.pro. BD’s Nexiva closed catheter reduces blood-exposure risk by 98% and delivers median dwell times of 144.5 hours, boosting clinical productivity. Digital droplet infusion scales down volumes to 57 nL, demonstrating precision leaps that encourage adoption in high-value therapies. Coupled with IoT dashboards, these advancements anchor premium pricing power within the IV therapy devices market.
Restraint Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Product recalls & medication-error related regulatory scrutiny | -1.10% | Global, with stricter enforcement in FDA and EU markets | Short term (≤ 2 years) |
High cost of advanced infusion systems in low-resource settings | -0.80% | APAC emerging markets, Sub-Saharan Africa, Latin America | Long term (≥ 4 years) |
Shortage of skilled infusion nurses raising complication risks | -0.60% | North America & EU, with spillover effects globally | Medium term (2-4 years) |
Shift toward subcutaneous/oral biologics reducing IV demand | -0.40% | Global, led by oncology and immunology therapeutic areas | Long term (≥ 4 years) |
Source: Mordor Intelligence
Product Recalls & Medication-Error Regulatory Scrutiny
The FDA initiated Class I recalls affecting more than 150,000 infusion devices in 2024, including ICU Medical’s Medfusion line, intensifying oversight across the IV therapy devices market. New Quality Management System Regulation, effective February 2026, aligns US rules with ISO 13485:2016 and expands post-market surveillance. Fresenius Kabi’s USD 240 million Ivenix buy-out swiftly encountered warning letters, illustrating compliance risk. Section 524B cybersecurity mandates now form part of pre-market submissions, raising barriers for smaller entrants. While these actions uplift safety, short-run cost spikes can dampen equipment turnover, tempering growth within the IV therapy devices market.
Shift Toward Subcutaneous/Oral Biologics Reducing IV Demand
Large-volume subcutaneous formulations constitute 15% of late-stage pipelines, signaling a channel shift away from intravenous delivery. Merck’s subcutaneous pembrolizumab aims to cut chair-time from hours to minutes, pending September 2025 FDA action drugs.com. Oncology biologics such as daratumumab already demonstrate patient-preference swings toward rapid injections, challenging pump utilization rates. Pharma companies are also exploring eco-friendly delivery devices that sidestep single-use IV disposables. Consequently, manufacturers must showcase superior clinical or economic value to defend share within the IV therapy devices market.
Segment Analysis
By Product Type: Smart Pumps Lead Innovation Wave
IV catheters controlled 38.34% of 2024 revenue as the foundational access tool across settings, securing the single-largest slice of the IV therapy devices market bbraunusa.com. Smart infusion pumps, however, represent the fastest growth at 6.78% CAGR thanks to AI dose-error reduction and cloud analytics. Baxter’s Spectrum IQ earned its seventh Best-in-KLAS award with 97% drug-library compliance, illustrating the performance bar now expected in the IV therapy devices market. Consumables such as tubing and administration sets benefit from steady replacement cycles, ensuring recurring revenue. Needle-free connectors, securement devices, and advanced filters collectively add infection-prevention value, making them attractive add-on sales. Mature drip-chamber components grow modestly yet remain essential, preserving backbone demand throughout the IV therapy devices market.
By End User: Home Care Disrupts Traditional Models
Hospitals retained 49.23% share in 2024, reflecting embedded procurement pathways and the scale of acute-care demand. Home-care settings, advancing at a 7.12% CAGR, illustrate how payer cost controls and patient comfort reorder priorities within the IV therapy devices market. Japanese home-care data show 21.6% of patients need intravenous therapy, yet 75% experience venous-access complications, spotlighting the safety gap that premium devices aim to close. Ambulatory surgery centers absorb spill-over cases as same-day procedures proliferate, requiring compact yet sophisticated pumps. Diagnostic and specialty clinics exploit niche oncology and immunology therapies where controlled infusion remains critical. Value-based care incentives further fuel migration outside hospitals, strengthening multi-setting demand across the IV therapy devices market.
By Application: Oncology Drives Premium Growth
Medication administration comprised 44.45% revenue in 2024, spanning antibiotics to biologics. Yet chemotherapy and oncology applications post the steepest climb at 7.89% CAGR, propelled by rising cancer incidence and regimen complexity. Closed-loop delivery prototypes like CLAUDIA monitor plasma drug levels every five minutes, foreshadowing a new standard of precision in the IV therapy devices market. Fluid and nutrition therapy retains baseline demand in critical-care units, while blood-product infusion requires strict alarm and monitoring features. AI-optimized parenteral nutrition formulations illustrate how application-specific software differentiation can unlock fresh value pools.
Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
North America generated 42.23% of global revenue in 2024 owing to robust reimbursement and early technology adoption, reinforcing its anchor position in the IV therapy devices market. Yet Hurricane Helene exposed supply-chain risk, triggering federal initiatives to validate point-of-care fluid manufacturing and argue for broader supplier portfolios. Canada’s universal system and Mexico’s private-hospital build-out add incremental volumes, while a harmonizing regulatory backdrop facilitates cross-border trade.
Asia-Pacific is the fastest-growing region at an 8.12% CAGR, propelled by China’s healthcare-spend trajectory toward RMB 205 trillion by 2030 and incentive schemes that fast-track innovative devices . Japan’s super-aging society intensifies home-infusion uptake despite elevated complication rates, creating openings for safer vascular-access designs. India’s hospital expansion and chronic-disease surge position it as a high-potential adopter once reimbursement barriers ease. South Korea and Australia, with advanced payer systems, foster premium-device adoption that often cascades into neighboring markets, reinforcing Asia-Pacific’s strategic weight within the IV therapy devices market.
Europe delivers steady gains through stringent quality standards and sustainability mandates that spur eco-design innovation. Economic pressure in Southern markets dampens capital purchases, but Northern nations maintain high replacement cycles. Latin America and the Middle East & Africa contribute emerging-market upside: Brazil drives regional scale through public-hospital acquisitions, while GCC states channel oil revenues into specialty-care facilities requiring sophisticated IV infrastructure. South Africa acts as a distribution hub for sub-Saharan adoption. Collectively, these markets diversify revenue streams and cushion regional shocks for participants in the IV therapy devices market.

Competitive Landscape
The IV therapy devices market exhibits moderate consolidation, with the top five suppliers controlling majority of 2024 revenue. Strategic acquisitions characterize recent moves: BD paid USD 4.2 billion for Edwards Lifesciences’ critical-care assets to bundle monitoring with infusion delivery. Stryker’s USD 4.9 billion bid for Inari Medical secures entry into peripheral-vascular infusion therapies, signaling portfolio expansion beyond traditional orthopedics.
Regulatory stringency raises operating thresholds; smaller firms like InfuTronix exited after recalling 52,328 Nimbus units, underlining financial exposure to quality lapses. Platform strategies that integrate pumps, disposables, and analytics create sticky ecosystems that elevate switching costs for providers. AI capabilities now act as competitive differentiators: BD’s HemoSphere Alta showcases real-time cerebral-autoregulatory insights, whereas Baxter augments its Spectrum IQ with dose-change alerts.
White-space opportunities persist in home-infusion monitoring and mid-tier emerging markets where cost-optimized systems can undercut premium incumbents. Cybersecurity compliance and software-as-a-medical-device expertise are becoming critical gating factors for market entry. Collectively, these dynamics support healthy rivalry while reinforcing the importance of scale and technical depth within the IV therapy devices market.
Intravenous (IV) Equipment Industry Leaders
-
Becton, Dickinson and Company
-
3M
-
Henry Schein, Inc.
-
B. Braun Melsungen AG
-
ICU Medical, Inc.
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- April 2025: BD launched the HemoSphere Alta platform with AI-driven decision support for critical-care hemodynamics
- April 2025: Teleflex secured FDA 510(k) clearance for the AC3 Range intra-aortic balloon pump
- March 2025: Merck’s subcutaneous pembrolizumab met non-inferiority versus IV dosing in Phase 3 trial
Global Intravenous (IV) Equipment Market Report Scope
IV administration means that the patient receives substances directly into their veins through a tube called a cannula. This could be either medication or nutrition. IV Therapy is a common practice for administering fluids to dehydrated patients, medications, chemotherapy treatments, and blood transfusions.
The intravenous (IV) equipment market is segmented by type (IV catheters, infusion pumps, securement devices, administration sets, drip chambers, and other types), end-user (hospitals, ambulatory surgical centers, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
By Product Type | Infusion Pumps | ||
IV Catheters (Peripheral & Central) | |||
Administration Sets & IV Tubing | |||
Securement & Stabilization Devices | |||
Needle-Free/Closed IV Connectors | |||
Drip Chambers & Filters | |||
By End User | Hospitals & Clinics | ||
Ambulatory Surgical Centers | |||
Home-Care Settings | |||
Diagnostic & Specialty Centers | |||
By Application | Medication Administration | ||
Fluid & Nutrition Therapy | |||
Blood-based Products & Transfusions | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
South Korea | |||
Australia | |||
Rest of Asia-Pacific | |||
South America | Brazil | ||
Argentina | |||
Rest of South America | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa |
Infusion Pumps |
IV Catheters (Peripheral & Central) |
Administration Sets & IV Tubing |
Securement & Stabilization Devices |
Needle-Free/Closed IV Connectors |
Drip Chambers & Filters |
Hospitals & Clinics |
Ambulatory Surgical Centers |
Home-Care Settings |
Diagnostic & Specialty Centers |
Medication Administration |
Fluid & Nutrition Therapy |
Blood-based Products & Transfusions |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
South Korea | |
Australia | |
Rest of Asia-Pacific | |
South America | Brazil |
Argentina | |
Rest of South America | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa |
Key Questions Answered in the Report
What is the current value of the IV therapy devices market?
The IV therapy devices market size is USD 16.34 billion in 2025 and is projected to reach USD 22.07 billion by 2030 under a 6.20% CAGR.
Which product segment is expanding the fastest?
Smart infusion pumps lead growth at a 6.78% CAGR due to AI-enabled safety features and connectivity upgrades.
Why is Asia-Pacific viewed as the key growth region?
Rising healthcare spending, chronic-disease prevalence, and pro-innovation policies in China, India, and Japan push Asia-Pacific toward an 8.12% CAGR, the highest worldwide.
How are recalls influencing device innovation?
Heightened FDA scrutiny after Class I recalls compels manufacturers to embed AI dose-error checks, strengthen cybersecurity, and adopt ISO-aligned quality systems.
Will subcutaneous biologics erode future IV demand?
Large-volume subcutaneous formulations and oral biologics will lower some hospital infusions, yet complex chemotherapies and critical-care needs should sustain core IV volumes, especially for precision pumps.